Medicine · Français

Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?

deadline 2026-12-15 confidence medium tier 4 evidence
73%PolySignal estimate

Resolution criterion

Yes if the FDA approves the NDA by 15 December 2026 (Drugs@FDA or a BridgeBio release). A complete response letter, a postponed PDUFA date, or no decision by that date all count as no.

Verified starting state

NDA accepted with priority review, PDUFA date 27 November 2026. The FDA has indicated it does not plan an advisory committee. This would be the first approved treatment for any form of LGMD, on a surrogate biomarker (alpha-dystroglycan glycosylation). (27 May 2026)

What pushes it up

What pushes it down

What would move this number most

Whether the FDA will require additional analyses that trigger a major amendment and a three-month PDUFA extension, or issue a Complete Response Letter.

How this number is built

Deadline2026-12-15
Base rate73%
Best evidencetier 4 · 4 article(s) used
Independent runs68 · 78 (spread 10 pts)
Confidencemedium
Evidence capnot triggered
Last revised2026-09-21 22:20
Modelgemini-3.5-flash

Sources consulted

FDA accepts BridgeBio’s BBP-418 for priority reviewtier 4 · The Pharma Letter · 2026-05-28FDA decision on BBP-418 for LGMD2i expected in late Novembertier 4 · musculardystrophynews.com · 2026-05-28BridgeBio Pharma Announces FDA Acceptance of BBP-418 NDA for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Priority Review Statustier 4 · Quiver Quantitative · 2026-05-27BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9tier 4 · Yahoo Finance · 2026-03-30

Probability history

2026-09-21 22:20 73% 5 article(s) on file · gemini-3.5-flash

Reasons not recorded for this revision (detailed history has only been kept since recently).

2026-09-19 07:34 90% 5 article(s) on file · gemini-3-flash-preview

Reasons not recorded for this revision (detailed history has only been kept since recently).